Indian drugmakers are preparing for the launch of copycat weight-loss drugs as the world moves towards the patent expiry of ...

After years of shortages, the Food and Drug Administration (FDA) has now listed Novo Nordisk’s blockbuster diabetes and ...

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

"It's important that patients are aware that Novo Nordisk is the only company in the U.S. with FDA-approved medicines containing the main ingredient semaglutide. FDA has not approved any generic ...

Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...